This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Idiopathic Pulmonary Fibrosis, IPF or Interstitial Lung Disease
and you are
between 40 and 80
years old
The phase for this study is not defined.
Show me locations

The purpose

The pathogenesis of idiopathic pulmonary fibrosis (IPF) is incompletely understood but recurrent epithelial injury occurs which evokes the coagulation cascade. Thrombin is produced as a result and is over expressed in IPF patients, so may be important in propagating disease activity. We aim to recruit patients with IPF and then complete FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET (positron emission tomography) scans pre and post manipulation of the coagulation cascade to assess the role of this biological pathway in disease activity. Previous studies from our institution have demonstrated increased FDG avidity in the lungs of patients with IPF (assessed using FDG PET scans) but to date the cells and pathways responsible for this signal have not been identified and thus need further exploration.

Provided treatments

  • Drug: Dabigatran
  • Radiation: FDG PET scan

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02885961. The sponsor of the trial is University College London and it is looking for 12 volunteers for the current phase.
Official trial title:
Investigating the Role of the Coagulation Cascade in Idiopathic Pulmonary Fibrosis